Cure8 news brief
The study offers a validated tool to estimate risk of postoperative recurrence after ileocolonic resection and shows that postoperative biologic prophylaxis markedly lowers early endoscopic recurrence—information that could influence follow-up and treatment choices after surgery.
Adults with Crohn’s disease undergoing or recovering from ileocolonic resection, clinicians managing postoperative IBD care, and researchers studying postoperative prevention strategies and biologic therapy.
This study followed 632 adults undergoing ileocolonic resection and used logistic regression to identify clinical risk factors (male sex, active smoking, prior resection, and prior biologic exposure) for endoscopic recurrence within 1 year.
The authors report that receiving biologic therapy after surgery cut the odds of endoscopic recurrence by about two-thirds, independent of baseline risk factors. They also created a nomogram with moderate discrimination (AUC ~0.72) that was validated in two external cohorts to estimate individual recurrence risk.
How this may affect care: The findings support considering early postoperative biologic prophylaxis and closer surveillance, especially for patients with prior biologic exposure or other risk factors. Clinicians might use the nomogram to personalize follow-up and treatment intensity.
The article summarizes a prospective multicenter clinical study (ClinicalTrials.gov NCT03458195) with external validation cohorts; readers should consult the full peer-reviewed report for detailed methods, subgroup analyses, and safety data before changing care plans.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Postoperative endoscopic recurrence is common after ileocolonic resection for Crohn’s disease; this study suggests biologic drugs started after surgery are linked to lower recurrence rates. Knowing which biologics...
The findings suggest that over three decades more patients receive medical prevention after ileocolic resection — including thiopurines and biologics — and that rates of needing a second surgery have fallen. This matters...
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.
